Combination therapy with pioglitazone plus metformin or sulfonylurea in patients with Type 2 diabetes: Influence of prior antidiabetic drug regimen

Marc S. Rendell, N. Bradly Glazer, Zhan Ye

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Purpose: To evaluate two trials of combination therapy, pioglitazone together with metformin or sulfonylurea, for Type 2 diabetes mellitus and to examine how pretrial antidiabetic therapies may have influenced the results. Subjects and Methods: The results of two published trials that examine combination therapy, pioglitazone plus metformin or pioglitazone plus sulfonylurea were analyzed. A post hoc analysis was performed in which patients from both of these trials were subdivided on the basis of their oral antidiabetic therapy before enrollment into the trials. Those subsets receiving pretrial therapy with a sulfonylurea plus metformin - and discontinuing one of the agents before randomization - were compared to those receiving only one of the agents before enrollment. Results: Patients in the combination pioglitazone (30 mg/day) plus metformin therapy arm of one trial, who entered with stable metformin monotherapy, experienced a significant decrease in glycosylated hemoglobin (HbA1C) levels during the 16-week course of the trial (-1.0±0.1 [mean±S.E.] percentage points; P1C levels (0.2±0.2 percentage points; P>.05). The difference between groups was significant (P1C levels (-1.0±0.1 and -1.4±0.1 percentage points, respectively, for the 15- and 30-mg pioglitazone arms; P1C levels. Differences between the groups separated on the basis of pretrial antidiabetic regimen were significant (P

Original languageEnglish
Pages (from-to)211-217
Number of pages7
JournalJournal of Diabetes and its Complications
Volume17
Issue number4
DOIs
StatePublished - Jul 2003

Fingerprint

pioglitazone
Metformin
Hypoglycemic Agents
Type 2 Diabetes Mellitus
Therapeutics
Glycosylated Hemoglobin A
Random Allocation

All Science Journal Classification (ASJC) codes

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Combination therapy with pioglitazone plus metformin or sulfonylurea in patients with Type 2 diabetes : Influence of prior antidiabetic drug regimen. / Rendell, Marc S.; Glazer, N. Bradly; Ye, Zhan.

In: Journal of Diabetes and its Complications, Vol. 17, No. 4, 07.2003, p. 211-217.

Research output: Contribution to journalArticle

@article{37d0e76edbd24578a90d7f931e3a9e89,
title = "Combination therapy with pioglitazone plus metformin or sulfonylurea in patients with Type 2 diabetes: Influence of prior antidiabetic drug regimen",
abstract = "Purpose: To evaluate two trials of combination therapy, pioglitazone together with metformin or sulfonylurea, for Type 2 diabetes mellitus and to examine how pretrial antidiabetic therapies may have influenced the results. Subjects and Methods: The results of two published trials that examine combination therapy, pioglitazone plus metformin or pioglitazone plus sulfonylurea were analyzed. A post hoc analysis was performed in which patients from both of these trials were subdivided on the basis of their oral antidiabetic therapy before enrollment into the trials. Those subsets receiving pretrial therapy with a sulfonylurea plus metformin - and discontinuing one of the agents before randomization - were compared to those receiving only one of the agents before enrollment. Results: Patients in the combination pioglitazone (30 mg/day) plus metformin therapy arm of one trial, who entered with stable metformin monotherapy, experienced a significant decrease in glycosylated hemoglobin (HbA1C) levels during the 16-week course of the trial (-1.0±0.1 [mean±S.E.] percentage points; P1C levels (0.2±0.2 percentage points; P>.05). The difference between groups was significant (P1C levels (-1.0±0.1 and -1.4±0.1 percentage points, respectively, for the 15- and 30-mg pioglitazone arms; P1C levels. Differences between the groups separated on the basis of pretrial antidiabetic regimen were significant (P",
author = "Rendell, {Marc S.} and Glazer, {N. Bradly} and Zhan Ye",
year = "2003",
month = "7",
doi = "10.1016/S1056-8727(03)00005-9",
language = "English",
volume = "17",
pages = "211--217",
journal = "Journal of Diabetes and its Complications",
issn = "1056-8727",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Combination therapy with pioglitazone plus metformin or sulfonylurea in patients with Type 2 diabetes

T2 - Influence of prior antidiabetic drug regimen

AU - Rendell, Marc S.

AU - Glazer, N. Bradly

AU - Ye, Zhan

PY - 2003/7

Y1 - 2003/7

N2 - Purpose: To evaluate two trials of combination therapy, pioglitazone together with metformin or sulfonylurea, for Type 2 diabetes mellitus and to examine how pretrial antidiabetic therapies may have influenced the results. Subjects and Methods: The results of two published trials that examine combination therapy, pioglitazone plus metformin or pioglitazone plus sulfonylurea were analyzed. A post hoc analysis was performed in which patients from both of these trials were subdivided on the basis of their oral antidiabetic therapy before enrollment into the trials. Those subsets receiving pretrial therapy with a sulfonylurea plus metformin - and discontinuing one of the agents before randomization - were compared to those receiving only one of the agents before enrollment. Results: Patients in the combination pioglitazone (30 mg/day) plus metformin therapy arm of one trial, who entered with stable metformin monotherapy, experienced a significant decrease in glycosylated hemoglobin (HbA1C) levels during the 16-week course of the trial (-1.0±0.1 [mean±S.E.] percentage points; P1C levels (0.2±0.2 percentage points; P>.05). The difference between groups was significant (P1C levels (-1.0±0.1 and -1.4±0.1 percentage points, respectively, for the 15- and 30-mg pioglitazone arms; P1C levels. Differences between the groups separated on the basis of pretrial antidiabetic regimen were significant (P

AB - Purpose: To evaluate two trials of combination therapy, pioglitazone together with metformin or sulfonylurea, for Type 2 diabetes mellitus and to examine how pretrial antidiabetic therapies may have influenced the results. Subjects and Methods: The results of two published trials that examine combination therapy, pioglitazone plus metformin or pioglitazone plus sulfonylurea were analyzed. A post hoc analysis was performed in which patients from both of these trials were subdivided on the basis of their oral antidiabetic therapy before enrollment into the trials. Those subsets receiving pretrial therapy with a sulfonylurea plus metformin - and discontinuing one of the agents before randomization - were compared to those receiving only one of the agents before enrollment. Results: Patients in the combination pioglitazone (30 mg/day) plus metformin therapy arm of one trial, who entered with stable metformin monotherapy, experienced a significant decrease in glycosylated hemoglobin (HbA1C) levels during the 16-week course of the trial (-1.0±0.1 [mean±S.E.] percentage points; P1C levels (0.2±0.2 percentage points; P>.05). The difference between groups was significant (P1C levels (-1.0±0.1 and -1.4±0.1 percentage points, respectively, for the 15- and 30-mg pioglitazone arms; P1C levels. Differences between the groups separated on the basis of pretrial antidiabetic regimen were significant (P

UR - http://www.scopus.com/inward/record.url?scp=0142029431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142029431&partnerID=8YFLogxK

U2 - 10.1016/S1056-8727(03)00005-9

DO - 10.1016/S1056-8727(03)00005-9

M3 - Article

C2 - 12810245

AN - SCOPUS:0142029431

VL - 17

SP - 211

EP - 217

JO - Journal of Diabetes and its Complications

JF - Journal of Diabetes and its Complications

SN - 1056-8727

IS - 4

ER -